A phase II trial of m-AMSA in patients with small-cell lung cancer.
Eighteen patients with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment. m-AMSA in this dose and schedule is not sufficiently active in small-cell lung cancer to warrant further study in a heavily treated patient population.